Yu Yanhong, ex-China traditional medicine chief, surrenders to graft probe

Yu Yanhong, the former director of China's National Administration of Traditional Chinese Medicine, has turned herself in to the country's anti-corruption authorities and is under investigation, China's Central Commission for Discipline Inspection and National Supervisory Commission announced on Friday, 6 November 2026. The announcement said she is suspected of serious violations of party discipline and the law, and that she is now under disciplinary review and supervisory investigation. It did not say what the suspected violations are. Two days earlier, she had been removed as a member of the national committee of China's top political advisory body. Yu, 64, led the administration, which oversees traditional Chinese medicine (TCM) across the country, from July 2023 until February this year. She is the second head of the agency in a row to be investigated: her predecessor, Yu Wenming, was handed over for prosecution in December 2025.

The National Administration of Traditional Chinese Medicine is the government body that sets the direction for China's own system of traditional medicine, from its hospitals and training to research and the promotion of TCM abroad. Its leader is among the most influential figures in traditional medicine anywhere. That two successive heads of the same agency have now come under investigation within about 17 months is a rare blow to an institution at the centre of China's health policy.

Yu Yanhong was a prominent public voice for TCM, including during the Covid-19 pandemic, when she promoted its use and cited an effectiveness rate above 90%, according to a Chinese business news report on her case. Her case does not, on its own, say anything about the medical value of TCM. It concerns the conduct of an official, and no wrongdoing has been proven. What it does show is that the agency running one of the world's largest traditional medicine systems now faces close scrutiny of how it has been governed.

For readers in India, the story is a reminder of how much weight governments now give to traditional health systems. India runs its own Ministry of Ayush for Ayurveda, Yoga, Unani, Siddha and Homeopathy, and China's TCM administration plays a similar role for its tradition. In both countries, public trust in these systems depends not only on research evidence but also on the integrity of the institutions that regulate them.

Peepals timeline: Yu Yanhong joined the leadership of the TCM administration in 2018 and became its director in July 2023, succeeding Yu Wenming. Yu Wenming was placed under investigation in June 2025 and was transferred for prosecution in December 2025. Yu Yanhong stepped down as director in February 2026. On 4 November 2026 her membership of the national political advisory body was revoked, and on 6 November 2026 the anti-corruption authorities announced that she had surrendered and was under investigation.

Short-term: The investigation puts China's TCM administration under renewed scrutiny, less than a year after its previous head was sent for prosecution.

Long-term: Repeated cases at the top of the agency may lead to closer oversight of how TCM policy, funding and approvals are handled, though the authorities have not announced any such changes.

Who is affected: China's TCM administration and the hospitals, universities and companies that work under its policies; and, more widely, people in China and abroad who follow how traditional medicine systems are governed.

Questions and Answers